Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference

Methylation of the MGMT promoter was found in 30 out of 56 patients and is associated with better survival outcomes.

• MGMT promoter methylation was linked to a median overall survival of 20.3 months compared to 7.3 months for unmethylated patients.
• Patients with methylated MGMT promoters had a median progression-free survival of 15.0 months versus 6.1 months for those without methylation.
• Methylation status correlated with higher treatment response rates and prolonged post-recurrence survival, with a median of 4.5 months compared to 1.4 months for unmethylated patients.
• The findings indicate that MGMT promoter methylation status is a crucial factor for risk stratification in patients with unresectable glioblastoma.

AI simplified